Merck & Co., Inc. news

   Watch this stock
Showing stories 1 - 10 of about 154   

Articles published

MRK 58.60 +0.06 (0.10%)
price chart
Merck & Co., Inc. Gardasil 9 Gets Green Signal From CDC Committee
Pharmaceutical giant Merck & Co., Inc. (NYSE:MRK) announced Thursday that the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) has included its Gardasil 9 vaccine in the list of recommended ...
Trade of the Day: MRK Stock Fires Off Triple Buy Signals
Merck & Co., Inc. (NYSE:MRK) - This is one of the world's largest drug manufacturers, and recent acquisitions have added to its position in niche markets.
Merck & Co. Inc. (NYSE:MRK) on Watch
[AP] Merck & Co., Inc.(NYSE:MRK) (TREND ANALYSIS), has granted a free license allowing one of its HIV medicines to be made and sold inexpensively for use in young children in poor countries hard hit by the AIDS virus.
Merck & Co. Receives Consensus Recommendation of "Hold" from ...  WKRB News
Traders Buzz: Merck & Co. Inc. (NYSE:MRK), Anadarko Petroleum ...  Gaining Green
5 Things Merck & Co., Inc.'s Management Wants You to Know
Pharmaceutical giant Merck (NYSE: MRK ) offers a number of promising new drug candidates, but unfortunately for investors it delivered another highly forgettable quarter this past week.
Merck & Co., Inc. Collaborates With MPP To Increase Access To Its HIV Drug In ...
Merck & Co., Inc. (NYSE:MRK), the second-largest US drug maker, has announced an agreement with the Medicines Patent Pool (MPP) for its HIV drug, raltegravir, in its efforts to expedite the process of developing low-priced pediatric formulations for ...
New Jersey Drugmaker Grants Free License to HIV Medicine for Children  NBC 10 Philadelphia
One Put, One Call Option To Know About for Merck & Co.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Merck & Co., Inc (NYSE: MRK). So this week we highlight one interesting put contract, and one interesting call contract, from the ...
Merck & Co. Inc. (NYSE:MRK) Partners With MPP to help Developing Countries ...
Merck & Co. Inc. (NYSE:MRK), which is the second biggest drug maker in United States, has announced that it has made an agreement with the MPP (medicine patent pool) for its HIV treatment.
Analyst Rating Update on Merck & Co., Inc.
Merck & Company (NYSE:MRK) has received a short term rating of hold from research analysts at Zacks with a rank of 3. The company has been rated an average of 2 by 12 Wall Street Analysts. 6 analysts have added the counter in their list of strong buys.
Merck & Co. Inc. (NYSE:MRK) Tights Its Shoes To Present New Data of ...  StreetWise Report
Merck & Co., Inc. (MRK) Q4 Earnings Preview: Expect Lower Sales And Earnings
Merck & Co., Inc. (NYSE:MRK) is due to announce its earnings for the fourth quarter of fiscal 2014 (4QFY14) before the market opens February 4. Analysts expect the company to report $10.46 billion in revenue for the quarter, a 7.5% decline from $11.3 ...
Zacks Rating Disclosure on Merck & Co., Inc.  Stafford Daily
Merck & Co., Inc. (MRK) 4Q Results To Reflect Patents Expiry Impact  InvestCorrectly
Merck & Co., Inc. (MRK) No Longer Has Breakthrough Therapy Status For Its ...
Merck & Co., Inc. (NYSE:MRK) announced Wednesday that the US Food and Drug Administration (FDA) has issued a notice detailing plans to rescind its Breakthrough Therapy Designation for the company's hepatitis C treatment drug.
Company Update (NYSE:MRK): Merck says hepatitis C treatment to lose ...  Jutia Group
FDA to Rescind Breakthrough Status for Merck Hepatitis Drug  Bloomberg